Methods: A total of 50 patients undergoing computed tomography (CT) and endoscopic ultrasonography (EUS) at our institute were included in this study. CE-EUS was performed when mural lesions were detected on EUS. The ability to diagnose the presence of mural nodules with each imaging modality was evaluated. In addition, the measurement accuracy of the height of mural nodules with

each imaging modality was compared. Results: Resection was performed in 17 cases, with the remaining 33 patients placed FK228 in vivo under a follow-up of more than 12 months. Of the 17 patients undergoing surgery, the histopathological findings revealed 14 cases with mural nodules and three cases without. When using EUS alone, the rate of accurately diagnosing mural nodules was 72%, but this increased to 98% when using EUS combined with CE-EUS. In terms of the measurement accuracy of the height of mural nodules, CE-EUS performed significantly better than CT DAPT datasheet or EUS (P < 0.05). Using receiver operating characteristic

curve analysis and determining the cut-off value for mural nodule height measured on CE-EUS as 8.8 mm facilitated the accuracy for diagnosing malignant BD-IPMN of 94%. Conclusion: CE-EUS can be used not only to diagnose the presence of mural nodules, but also as an accurate means of measuring the height of mural nodules. Furthermore, using CE-EUS to measure the height of mural nodules provides a highly precise means of determining the difference between benign and malignant BD-IPMN. Key Word(s): 1. contrast-enhanced endoscopic ultrasonography; 2. branch duct intraductal papillary mucinous neoplasm Presenting Author: XIANGYI

HE Additional Authors: YAOZONG YUAN Corresponding Author: XIANGYI HE Affiliations: Ruijin Hospital Objective: EGFR tyrosine kinase inhibitor erlotinib is shown to be promising therapy in combination of gemcitabine in pancreatic cancer. selleck chemicals llc K-RAS mutation is frequently present in pancreatic cancer and is related to anti-EGFR therapy resistance. Our previous study showed DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. The aim of this study is to evaluate whether silence of DJ-1 can increase anti-EGFR therapy efficiency in pancreatic cancer. Methods: Anti-DJ-1 shRNA and negative control shRNA (nc) was stably transfected into BxPC-3 cell (BxPC3/DJ-1 and BxPC3/NC). BxPC3/DJ-1 and BxPC3/NC shRNA were treated with various doses of erlotinib, and then cell proliferation was measured by CCK-8, Brdu incorporation.